Evidence map›Paper›PMID 12453363›Full record

ArticleEmerging infectious diseases2002

DNA fngerprinting of Mycobacterium tuberculosis: lessons learned and implications for the future.

Scott J N McNabb, Christopher R Braden, Thomas R Navin

Abstract read
In one paragraph

Article in Emerging infectious diseases, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. How host heterogeneity governs tuberculosis reinfection?Proceedings. Biological sciences · 2012
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Stable association between strains of Mycobacterium tuberculosis and their human host populations.Proceedings of the National Academy of Sciences of the United States of America · 2004
    Article
  10. Mycobacterium tuberculosis Beijing genotype.Emerging infectious diseases · 2003
    Article
  11. Tuberculosis control: challenges of an ancient and ongoing epidemic.Public health reports (Washington, D.C. : 1974)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Scott J N McNabbCenters for Disesase Control and Prevention, Atlanta, GA 30333, USA. sym3@cdc.gov
Christopher R Braden
Thomas R Navin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA fingerprinting of Mycobacterium tuberculosis--a relatively new laboratory technique--offers promise as a powerful aid in the prevention and control of tuberculosis (TB). Established in 1996 by the Centers for Disease Control and Prevention (CDC), the National Tuberculosis Genotyping and Surveillance Network was a 5-year prospective, population-based study of DNA fingerprinting conducted from 1996 to 2000. The data from this study suggest multiple molecular epidemiologic and program management uses for DNA fingerprinting in TB public health practice. From these data, we also gain a clearer understanding of the overall diversity of M. tuberculosis strains as well as the presence of endemic strains in the United States. We summarize the key findings and the impact that DNA fingerprinting may have on future approaches to TB control. Although challenges and limitations to the use of DNA fingerprinting exist, the widespread implementation of the technique into routine TB prevention and control practices appears scientifically justified.

Indexed as

DNA FingerprintingCenters for Disease Control and Prevention, U.S.Cluster AnalysisDiagnostic ErrorsDisease OutbreaksEquipment ContaminationGenetic VariationHumansIncidenceLaboratoriesMolecular EpidemiologyMycobacterium tuberculosisRisk FactorsTuberculosisUnited States

Identifiers

PMID12453363
PMCPMC2738558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.